Pharmascience, a generic pharmaceutical company basin in Quebec, has acquired Aegera Therapeutics, a Montreal-based clinical-stage biotechnology company focused on developing therapeutics to address unmet medical needs, primarily in oncology. Aegera’s 20 employees will join Pharmascience.

“The acquisition of Aegera will enable Pharmascience to increase and diversify its research and development activities through the continuance of Aegera’s programs,” said David Goodman, chief executive officer of Pharmascience. This acquisition will strengthen Pharmascience’s position as a pharmaceutical leader, and will solidify our organization’s diversification and expansion strategy.”